Ruben R Plentz1, Nisar P Malek1. 1. Department of Internal Medicine I, Medical University Hospital, Tübingen, Germany.
Abstract
BACKGROUND: Cholangiocarcinoma (CC) is the second most common primary malignant liver disease. During the last decades, various novel therapies have been introduced in the field of oncology; nevertheless, the number of treatment options for CC is still limited. METHODS: In this article, current palliative chemotherapy concepts as well as new drug therapies are outlined. RESULTS: Gemcitabine and cisplatin are the standard treatment of care for patients with inoperable CC. Second-line chemotherapy is not standardized yet and is dependent on the first-line compounds. Antibodies against VEGFR and EGFR showed mixed or negative results. New molecular systemic treatments are not established yet. CONCLUSION: Many clinical trials are still ongoing and new therapeutic strategies, including immunotherapies, are under active investigation.
BACKGROUND:Cholangiocarcinoma (CC) is the second most common primary malignant liver disease. During the last decades, various novel therapies have been introduced in the field of oncology; nevertheless, the number of treatment options for CC is still limited. METHODS: In this article, current palliative chemotherapy concepts as well as new drug therapies are outlined. RESULTS:Gemcitabine and cisplatin are the standard treatment of care for patients with inoperable CC. Second-line chemotherapy is not standardized yet and is dependent on the first-line compounds. Antibodies against VEGFR and EGFR showed mixed or negative results. New molecular systemic treatments are not established yet. CONCLUSION: Many clinical trials are still ongoing and new therapeutic strategies, including immunotherapies, are under active investigation.
Authors: Tanios Bekaii-Saab; Mitch A Phelps; Xiaobai Li; Motoyasu Saji; Laura Goff; John Sae Wook Kauh; Bert H O'Neil; Stephanie Balsom; Catherine Balint; Ryan Liersemann; Vasily V Vasko; Mark Bloomston; William Marsh; L Austin Doyle; Gilian Ellison; Michael Grever; Matthew D Ringel; Miguel A Villalona-Calero Journal: J Clin Oncol Date: 2011-04-25 Impact factor: 44.544
Authors: Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater Journal: N Engl J Med Date: 2010-04-08 Impact factor: 91.245
Authors: Francesco Sabbatino; Vincenzo Villani; Jennifer H Yearley; Vikram Deshpande; Lei Cai; Ioannis T Konstantinidis; Christina Moon; Sjoerd Nota; Yangyang Wang; Ahmad Al-Sukaini; Andrew X Zhu; Lipika Goyal; David T Ting; Nabeel Bardeesy; Theodore S Hong; Carlos Fernandez-del Castillo; Kenneth K Tanabe; Keith D Lillemoe; Soldano Ferrone; Cristina R Ferrone Journal: Clin Cancer Res Date: 2015-09-15 Impact factor: 12.531
Authors: M Moehler; A Maderer; C Schimanski; S Kanzler; U Denzer; F T Kolligs; M P Ebert; A Distelrath; M Geissler; J Trojan; M Schütz; L Berie; C Sauvigny; F Lammert; A Lohse; M M Dollinger; U Lindig; E M Duerr; N Lubomierski; S Zimmermann; D Wachtlin; A-K Kaiser; S Schadmand-Fischer; P R Galle; M Woerns Journal: Eur J Cancer Date: 2014-10-15 Impact factor: 9.162
Authors: Dieter Koeberle; Piercarlo Saletti; Markus Borner; Daniela Gerber; Daniel Dietrich; Clemens B Caspar; Walter Mingrone; Kurt Beretta; Florian Strasser; Thomas Ruhstaller; Oreste Mora; Richard Herrmann Journal: J Clin Oncol Date: 2008-08-01 Impact factor: 44.544
Authors: Jesse S Voss; Leonard M Holtegaard; Sarah E Kerr; Emily G Barr Fritcher; Lewis R Roberts; Gregory J Gores; Jun Zhang; W Edward Highsmith; Kevin C Halling; Benjamin R Kipp Journal: Hum Pathol Date: 2013-02-04 Impact factor: 3.526
Authors: Pan Wang; Xinhua Song; Kirsten Utpatel; Runze Shang; Yoon Mee Yang; Meng Xu; Jie Zhang; Li Che; John Gordan; Antonio Cigliano; Ekihiro Seki; Matthias Evert; Diego F Calvisi; Xiaosong Hu; Xin Chen Journal: Cell Death Dis Date: 2019-02-11 Impact factor: 9.685